Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double-Barreled CAR t takes on Hard-to-Treat myeloma

NCT ID NCT05850234

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells (CD19 and BCMA). The trial has two phases: the first checks safety and the right dose, and the second measures how well the treatment shrinks tumors. About 182 adults will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD0120 (a dual-targeting CAR T-cell therapy that attacks two proteins on cancer cells: CD19 and BCMA)
What this could lead to
If successful, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply to everyone. CAR T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 232 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age at the time of consent. * ECOG performance status of 0 or 1. * Documented diagnosis of MM per IMWG diagnostic criteria. * Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. * Have documented evidence of progressive disease per IMWG criteria. * Participant must have measurable disease at screening. * Participant must have adequate bone marrow and organ function (hematological, hepatic and renal) demonstrated at screening. Exclusion Criteria : * Participant has a history of significant toxicity during prior CAR T-cell therapy and T-cell engaging therapy. * Participant has a history of a prior non-hematologic malignancy, unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. Some exceptions may apply. * Participant has significant cardiac, neurological, or psychiatric conditions. * Any other significant medical conditions such as: * Serious active or uncontrolled infection * Active autoimmune disease or a history of autoimmune disease within 2 years * Active plasma cell leukemia at the time of screening * Clinical evidence of dementia or altered mental status, or stroke, intracranial haemorrhage, or seizure within 6 months before signing informed consent form (ICF). * Known active or prior history of central nervous system involvement or exhibits clinical signs of meningeal involvement of MM. Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed/refractory multiple myeloma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed/refractory multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    34 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • Research Site

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Research Site

    RECRUITING

    La Jolla, California, 92037, United States

  • Research Site

    RECRUITING

    Los Angeles, California, 90095, United States

  • Research Site

    RECRUITING

    San Francisco, California, 94143, United States

  • Research Site

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Research Site

    RECRUITING

    Denver, Colorado, 80218, United States

  • Research Site

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Research Site

    RECRUITING

    Miami, Florida, 33136, United States

  • Research Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Research Site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Research Site

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Research Site

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • Research Site

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Research Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Research Site

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Research Site

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    WITHDRAWN

    Omaha, Nebraska, 68198, United States

  • Research Site

    WITHDRAWN

    Hackensack, New Jersey, 07601, United States

  • Research Site

    NOT_YET_RECRUITING

    Buffalo, New York, 14203, United States

  • Research Site

    RECRUITING

    New York, New York, 10065, United States

  • Research Site

    RECRUITING

    Stony Brook, New York, 11794, United States

  • Research Site

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Research Site

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Research Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Research Site

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • Research Site

    RECRUITING

    Austin, Texas, 78704, United States

  • Research Site

    RECRUITING

    Dallas, Texas, 75390, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Research Site

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Research Site

    RECRUITING

    Edmonds, Washington, 98026, United States

  • Research Site

    RECRUITING

    Seattle, Washington, 98109, United States

  • Research Site

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.